These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

709 related items for PubMed ID: 17642394

  • 1. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S, Vardi J, Finkelstein Y, Pollak L.
    Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
    [Abstract] [Full Text] [Related]

  • 2. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G, COGIMUS Study Group.
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [Abstract] [Full Text] [Related]

  • 3. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [Abstract] [Full Text] [Related]

  • 4. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [Abstract] [Full Text] [Related]

  • 5. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [Abstract] [Full Text] [Related]

  • 6. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O, Guerrero M, Mayorga C, Muñoz L, Leán A, Luque G, Hervás M, Fernández V, Capdevila A, de Ramón E.
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [Abstract] [Full Text] [Related]

  • 8. The auditory system involvement in Parkinson disease: electrophysiological and neuropsychological correlations.
    Nojszewska M, Pilczuk B, Zakrzewska-Pniewska B, Rowińska-Marcińska K.
    J Clin Neurophysiol; 2009 Dec; 26(6):430-7. PubMed ID: 19952569
    [Abstract] [Full Text] [Related]

  • 9. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 10. Neuropsychological testing and event-related potentials in the assessment of cognitive performance in the patients with multiple sclerosis--a pilot study.
    Pokryszko-Dragan A, Zagrajek M, Slotwinski K, Gruszka E, Bilinska M, Podemski R.
    Clin Neurol Neurosurg; 2009 Jul; 111(6):503-6. PubMed ID: 19233546
    [Abstract] [Full Text] [Related]

  • 11. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL, Copolymer-1 Treatment Study Principal Investigators.
    Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
    [Abstract] [Full Text] [Related]

  • 12. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [Abstract] [Full Text] [Related]

  • 13. Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
    Lanzillo R, Prinster A, Scarano V, Liuzzi R, Coppola G, Florio C, Salvatore E, Schiavone V, Brunetti A, Muto M, Orefice G, Alfano B, Bonavita V, Brescia Morra V.
    J Neurol Sci; 2006 Jun 15; 245(1-2):141-5. PubMed ID: 16626758
    [Abstract] [Full Text] [Related]

  • 14. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S, Cagiran I, Ormeci B, Idiman E.
    J Neurol Sci; 2004 Mar 15; 218(1-2):3-7. PubMed ID: 14759626
    [Abstract] [Full Text] [Related]

  • 15. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP, Italian Multiple Sclerosis Database Network (MSDN) Group.
    Ann Neurol; 2009 Oct 15; 66(4):513-20. PubMed ID: 19847899
    [Abstract] [Full Text] [Related]

  • 16. Effects of relapsing-remitting multiple sclerosis treatment with interferon beta-1b results of a three-year follow-up study.
    Jesić A, Stefanović D, Delibasić N, Semnic M, Sakallasz L, Dobrenov D, Zivanović Z, Rabi-Zikić T, Zikić M.
    Acta Clin Croat; 2009 Jun 15; 48(2):183-6. PubMed ID: 19928420
    [Abstract] [Full Text] [Related]

  • 17. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy.
    Trojano M, Paolicelli D, Zimatore GB, De Robertis F, Fuiani A, Di Monte E, Livrea P.
    Neurol Sci; 2005 Dec 15; 26 Suppl 4():S179-82. PubMed ID: 16388354
    [Abstract] [Full Text] [Related]

  • 18. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
    Feinstein A, O'Connor P, Feinstein K.
    J Neurol; 2002 Jul 15; 249(7):815-20. PubMed ID: 12140662
    [Abstract] [Full Text] [Related]

  • 19. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z, Bereczki D, Csiba L, Csépány T.
    Ideggyogy Sz; 2006 Nov 20; 59(11-12):442-7. PubMed ID: 17203882
    [Abstract] [Full Text] [Related]

  • 20. Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients.
    Yozbatiran N, Baskurt F, Baskurt Z, Ozakbas S, Idiman E.
    J Neurol Sci; 2006 Jul 15; 246(1-2):117-22. PubMed ID: 16678208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.